Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/002088COMPOSITION BASED ON THE ANTIOXIDANT ACTIVITY OF THE ENZYME SUPEROXIDE DISMUTASE AND APPLICATION THEREOF IN EYE DISEASES
WO 26.01.2023
Int.Class A61K 38/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
44Oxidoreductases (1)
Appl.No PCT/ES2022/070486 Applicant FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNIDAD VALENCIANA (FISABIO) Inventor ESCOBAR BEDIA, Francisco Javier
The present invention relates to a composition containing an enzyme belonging to the group of superoxide dismutases (SOD), or any SOD mimic and similar, together with hyaluronic acid and EDTA. Said composition forms part of a pharmaceutical formulation which promotes or maintains eye health by inhibiting cellular and tissue damage caused by free radicals, making it useful in the treatment and/or prevention of eye diseases involving oxidative stress, or as an adjuvant to other existing treatments, as well as in post-operative treatments to treat and/or prevent oxidative stress or inflammatory adverse reactions.
2.WO/2023/002433COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING CORONAVIRUS VARIANT INFECTIONS AND METHODS OF USING THE SAME
WO 26.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IB2022/056759 Applicant ENGENEIC MOLECULAR DELIVERY PTY LTD Inventor BRAHMBHATT, Himanshu
The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.
3.WO/2023/004113COMPOSITIONS AND METHODS FOR USING PURIFIED HUMAN RNA EDITING ENZYMES
WO 26.01.2023
Int.Class A61K 38/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
Appl.No PCT/US2022/038010 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor JAMIESON, Catriona
In alternative embodiments, provided are methods for eradicating or reducing the in vivo numbers of cancer stem cells comprising administering to an individual in need thereof an ADAR1 (adenosine deaminase associated with RNA1) inhibiting agent, wherein the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 Nano-luc reporter activity in cell lines and in human cancer stem cell assays. In alternative embodiments, provided are methods for inhibiting an RNA virus or a retrovirus, optionally a SARs-CoV-2 virus, comprising lentiviral ADAR1 overexpression and in vivo administration, optionally intravenous (IV) administration, of a lentiviral ADAR1 transduced stem cell, optionally the stem cell is a cord blood CD34+ cell or a mesenchymal stromal cell.
4.WO/2023/004368LINKER POLYPEPTIDES
WO 26.01.2023
Int.Class C07K 14/55
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
55IL-2
Appl.No PCT/US2022/073970 Applicant TRUTINO BIOSCIENCES INC. Inventor KIM, Phillip S.
This disclosure relates to linker polypeptides. In some embodiments, the linker polypeptide comprises a first targeting sequence; a second targeting sequence; and a first linker between the first targeting sequence and the second targeting sequence, the linker comprising a protease-cleavable polypeptide sequence. In some embodiments, the linker polypeptide comprises a first active domain; a second active domain; a pharmacokinetic modulator; and a first linker between the pharmacokinetic modulator and the first active domain, the first linker comprising a protease-cleavable polypeptide sequence. In some embodiments, the linker polypeptide comprises a first active domain; an inhibitory polypeptide sequence capable of blocking an activity of the first active domain; a first linker between the first active domain and the inhibitory polypeptide sequence, the linker comprising a protease-cleavable polypeptide sequence; and a first targeting sequence.
5.WO/2023/003357COMPOSITION COMPRISING SUPEROXIDE DISMUTASE AND/OR BACILLUS STRAIN SPORES, AND USE THEREOF FOR IMPROVING ORAL HEALTH
WO 26.01.2023
Int.Class A61K 8/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
64Proteins; Peptides; Derivatives or degradation products thereof
66Enzymes
Appl.No PCT/KR2022/010623 Applicant GENOFOCUS CO., LTD. Inventor PAN, Jae Gu
The present invention relates to an oral composition comprising the superoxide dismutase (SOD) enzyme and/or Bacillus spp. strain spores, and a use thereof for improving oral health or managing oral hygiene. The composition may be useful for preventing or treating oral diseases such as oral pain, halitosis, tartar, plaque, gingivitis, and periodontitis, without causing adverse effects in the oral cavity.
6.WO/2023/001288INTEGRIN GPIIB/IIIA ANTAGONIST AND APPLICATION THEREOF IN COMBINATION WITH ANTI-VEGF ANTIBODY
WO 26.01.2023
Int.Class A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
Appl.No PCT/CN2022/107388 Applicant BIO-THERA SOLUTIONS, LTD. Inventor YANG, Shaowei
Disclosed are an integrin GPIIb/IIIa antagonist and an application thereof in combination with a VEGF antagonist in treatment of eye diseases. The treatment method comprises: administering an effective dose of the integrin GPIIb/IIIa antagonist or the integrin GPIIb/IIIa antagonist and the VEGF antagonist to patients in need.
7.WO/2023/004393METHODS OF TREATING PARKINSON'S DISEASE AND/OR LEWY BODY DISEASE OR DISORDER(S)
WO 26.01.2023
Int.Class A61K 38/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
05Dipeptides
Appl.No PCT/US2022/074021 Applicant ATHIRA PHARMA, INC. Inventor MOEBIUS, Hans, J.
The present disclosure relates to a method of treating Parkinson's Disease and/or Lewy body disease or disorder(s), including Parkinson's disease dementia and dementia with Lewy bodies, comprising administering to a subject 2-90 mg per day of a water-soluble prodrug. ATH-1017, which is rapidly converted to the active drug ATH-1001 in the plasma after subcutaneous (SC) injection to allow SC dosing in aqueous vehicles.
8.WO/2023/000688PERIPHERAL BLOOD TCR MARKER OF ALZHEIMER'S DISEASE, AND DETECTION KIT AND APPLICATION THEREOF
WO 26.01.2023
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No PCT/CN2022/080368 Applicant CHENGDU EXAB BIOTECHNOLOGY CO., LTD Inventor ZHANG, Zhixin
A peripheral blood TCR marker of Alzheimer's disease, and a detection kit and application thereof. The peripheral blood TCR marker of Alzheimer's disease comprises at least one of proteins of which sequences are as shown in SEQ ID NOs. 1-50. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be collected for extracting RNA, an immune map library is established by treating samples, and then upon high-throughput sequencing and TCR data analysis, a characteristic TCR sequence in the peripheral blood of Alzheimer's disease is firstly determined, and then a test result of a sample to be tested is compared with the characteristic TCR sequence, so as to determine whether a person suffers from Alzheimer's disease. According to the method, a huge number of specific TCR sequences of Alzheimer's disease can be compared at the same time, and compared with the detection of one or more markers alone, the marker has higher specificity and accuracy, and the diagnosis efficiency is improved.
9.WO/2023/001783METHOD OF PREPARING A PHOSPHOLIPID-ENRICHED, WHEY-DERIVED COMPOSITION HAVING A LOW CONTENT OF MICROORGANISMS, THE COMPOSITION AS SUCH, AND NUTRITIONAL USE OF THE COMPOSITION
WO 26.01.2023
Int.Class A23J 1/20
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
1Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
20from milk, e.g. casein; from whey
Appl.No PCT/EP2022/070107 Applicant ARLA FOODS AMBA Inventor BERTELSEN, Hans
The invention relates to a method of preparing a whey-derived composition enriched with respect to whey phospholipids by membrane filtration, and preferably also enriched with respect to other membrane components from whey. The membrane filtration is furthermore followed by a special microfiltration-based germ filtration which the inventors have found to be efficient for reducing the microbial content of the whey-derived composition while keeping nutritionally important components in the whey-derived composition. The invention furthermore relates to the whey-derived composition as such, use of the whey-derived composition as in ingredient in nutritional products, and to nutritional products comprising the whey-derived composition.
10.WO/2023/000223FAMSIN ORCHESTRATES METABOLIC ADAPTATIONS TO FAMINE
WO 26.01.2023
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/CN2021/107690 Applicant TSINGHUA UNIVERSITY Inventor WANG, Yiguo
An isolated polypeptide, an isolated nucleic acid, a hyperglycemia marker, use of the detection reagent in the preparation of a kit, use of the first agent in the preparation of a medicine, a pharmaceutical composition, food or health product for improving starvation tolerance, use of the second agent in the preparation of a medicine, a pharmaceutical composition for treating or preventing diabetes, a method for improving starvation tolerance, a method of weight loss, a method for the treatment or prevention of diabetes, a method for screening drugs for improving starvation tolerance and a method for screening drugs for the treatment or prevention of diabetes.